Determination of cox2 expression in colorectal carcinoma predicts the recurrence rate after surgical resection or adjuvant therapy, the goal of this study is to assess the effectiveness of cox2 as a prognostic marker in colorectal carcinoma by using immunohistochemistry.
Not Applicable
- Conditions
- Health Condition 1: C189- Malignant neoplasm of colon, unspecifiedHealth Condition 2: C189- Malignant neoplasm of colon, unspecifiedHealth Condition 3: C189- Malignant neoplasm of colon, unspecified
- Registration Number
- CTRI/2023/05/052619
- Lead Sponsor
- Datta Meghe institute of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All cases diagnosed as colorectal carcinoma on histopathology.
2.All colectomy/Hemicolectomy/ Proctocolectomy resection specimens.
3.Primary cases of colorectal carcinoma without any history of previous treatment.
4.All patients presenting with colorectal carcinoma arising Denovo.
Exclusion Criteria
1.All inflammatory lesions, and other malignancies of the gastrointestinal tract.
2.All biopsy specimens.
3.All treated cases of colorectal carcinoma and cases with recurrence
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunohistochemical analysis in determining cox2 expression used as a prognostic marker in colorectal carcinoma in correlation with TNM staging.Timepoint: 3 YEARS
- Secondary Outcome Measures
Name Time Method It can be used to identify patients with poor clinical outcomes and those who will benefit from early diagnosis.Timepoint: 3 YEARS